Cell Stem Cell:日本研制新方法可大量廉价制作血小板

2014-02-15 佚名 爱医

京都大学的研究小组在14日的美国《细胞-干细胞》CellStemCell 杂志网络版上报告称,他们利用能够发育成各种组织和脏器细胞的iPS细胞,成功开发出了在短时间内大量廉价制作血小板的方法。这一成果将有利于稳定供应输血时所需的血小板。 日本研制新方法可大量廉价制作血小板血小板是血液细胞之一,能够凝固血液,防止出血,手术时使用的血小板现在完全依赖献血,但是通过献血获得的血小板在室温下只能保存约4天

京都大学的研究小组在14日的美国《细胞-干细胞》CellStemCell 杂志网络版上报告称,他们利用能够发育成各种组织和脏器细胞的iPS细胞,成功开发出了在短时间内大量廉价制作血小板的方法。这一成果将有利于稳定供应输血时所需的血小板。



日本研制新方法可大量廉价制作血小板

血小板是血液细胞之一,能够凝固血液,防止出血,手术时使用的血小板现在完全依赖献血,但是通过献血获得的血小板在室温下只能保存约4天。

尽管此前其他研究队伍也利用iPS细胞制作出了血小板,但是由于培育出的巨核细胞的增殖能力有限,所以难以用较低的成本大量获得血小板。京都大学iPS细胞研究所教授江藤浩之率领的研究小组,利用iPS细胞培养出造血前体细胞之后,向其植入c-MYC和BMI1这两种基因,两周时间后,再追加植入BCL-XL基因,结果成功地制作出了几乎可以无限增殖的巨核细胞。让这三种基因停止发挥作用后,巨核细胞就开始制作血小板。由于能够稳定增加巨核细胞,制作血小板的效率相当于以前技术的100倍以上,制造成本也大幅降低。

由于巨核细胞非常稳定,几乎可以无限增殖,因此能够大量生产血小板,单次输血时所需的1000亿个血小板5天时间就可以准备好。这种巨核细胞在被冷冻保存数月时间后,依然能够制造血小板。虽然与从人体内采集的血小板相比止血功能尚差一些,不过研究小组认为,通过增加用量,能够弥补性能上的差距。

研究小组准备以血小板减少症为对象,在2年后开始临床研究,争取在10年后达到实用化。

原始出处:

Sou Nakamura, Naoya Takayama, Shinji Hirata, Hideya Seo, Hiroshi Endo, Kiyosumi Ochi, Ken-ichi Fujita, Tomo Koike, Ken-ichi Harimoto, Takeaki Dohda, Akira Watanabe, Keisuke Okita, Nobuyasu Takahashi, Akira Sawaguchi, Shinya Yamanaka, Hiromitsu Nakauchi, Satoshi Nishimura, Koji Eto. Expandable Megakaryocyte Cell Lines Enable Clinically Applicable Generation of Platelets from Human Induced Pluripotent Stem Cells. Cell Stem Cell, 13 February 2014; DOI: 10.1016/j.stem.2014.01.011

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1794353, encodeId=d53f1e9435351, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Dec 23 21:27:00 CST 2014, time=2014-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903054, encodeId=d3f9190305429, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon May 12 14:27:00 CST 2014, time=2014-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959015, encodeId=cb6a1959015e5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Feb 27 23:27:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868773, encodeId=38e71868e7317, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Mar 26 22:27:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294157, encodeId=277b129415e2b, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Feb 17 11:27:00 CST 2014, time=2014-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481818, encodeId=ce541481818ec, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Mon Feb 17 11:27:00 CST 2014, time=2014-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7432, encodeId=22b8e43296, content=小日本真强得很,尤其干细胞领域,确实处于依靠位置, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.132.226.159, createdTime=Sat Feb 15 23:37:00 CST 2014, time=2014-02-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1794353, encodeId=d53f1e9435351, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Dec 23 21:27:00 CST 2014, time=2014-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903054, encodeId=d3f9190305429, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon May 12 14:27:00 CST 2014, time=2014-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959015, encodeId=cb6a1959015e5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Feb 27 23:27:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868773, encodeId=38e71868e7317, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Mar 26 22:27:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294157, encodeId=277b129415e2b, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Feb 17 11:27:00 CST 2014, time=2014-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481818, encodeId=ce541481818ec, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Mon Feb 17 11:27:00 CST 2014, time=2014-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7432, encodeId=22b8e43296, content=小日本真强得很,尤其干细胞领域,确实处于依靠位置, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.132.226.159, createdTime=Sat Feb 15 23:37:00 CST 2014, time=2014-02-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1794353, encodeId=d53f1e9435351, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Dec 23 21:27:00 CST 2014, time=2014-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903054, encodeId=d3f9190305429, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon May 12 14:27:00 CST 2014, time=2014-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959015, encodeId=cb6a1959015e5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Feb 27 23:27:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868773, encodeId=38e71868e7317, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Mar 26 22:27:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294157, encodeId=277b129415e2b, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Feb 17 11:27:00 CST 2014, time=2014-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481818, encodeId=ce541481818ec, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Mon Feb 17 11:27:00 CST 2014, time=2014-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7432, encodeId=22b8e43296, content=小日本真强得很,尤其干细胞领域,确实处于依靠位置, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.132.226.159, createdTime=Sat Feb 15 23:37:00 CST 2014, time=2014-02-15, status=1, ipAttribution=)]
    2014-02-27 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1794353, encodeId=d53f1e9435351, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Dec 23 21:27:00 CST 2014, time=2014-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903054, encodeId=d3f9190305429, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon May 12 14:27:00 CST 2014, time=2014-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959015, encodeId=cb6a1959015e5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Feb 27 23:27:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868773, encodeId=38e71868e7317, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Mar 26 22:27:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294157, encodeId=277b129415e2b, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Feb 17 11:27:00 CST 2014, time=2014-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481818, encodeId=ce541481818ec, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Mon Feb 17 11:27:00 CST 2014, time=2014-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7432, encodeId=22b8e43296, content=小日本真强得很,尤其干细胞领域,确实处于依靠位置, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.132.226.159, createdTime=Sat Feb 15 23:37:00 CST 2014, time=2014-02-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1794353, encodeId=d53f1e9435351, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Dec 23 21:27:00 CST 2014, time=2014-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903054, encodeId=d3f9190305429, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon May 12 14:27:00 CST 2014, time=2014-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959015, encodeId=cb6a1959015e5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Feb 27 23:27:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868773, encodeId=38e71868e7317, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Mar 26 22:27:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294157, encodeId=277b129415e2b, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Feb 17 11:27:00 CST 2014, time=2014-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481818, encodeId=ce541481818ec, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Mon Feb 17 11:27:00 CST 2014, time=2014-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7432, encodeId=22b8e43296, content=小日本真强得很,尤其干细胞领域,确实处于依靠位置, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.132.226.159, createdTime=Sat Feb 15 23:37:00 CST 2014, time=2014-02-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1794353, encodeId=d53f1e9435351, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Dec 23 21:27:00 CST 2014, time=2014-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903054, encodeId=d3f9190305429, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon May 12 14:27:00 CST 2014, time=2014-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959015, encodeId=cb6a1959015e5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Feb 27 23:27:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868773, encodeId=38e71868e7317, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Mar 26 22:27:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294157, encodeId=277b129415e2b, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Feb 17 11:27:00 CST 2014, time=2014-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481818, encodeId=ce541481818ec, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Mon Feb 17 11:27:00 CST 2014, time=2014-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7432, encodeId=22b8e43296, content=小日本真强得很,尤其干细胞领域,确实处于依靠位置, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.132.226.159, createdTime=Sat Feb 15 23:37:00 CST 2014, time=2014-02-15, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1794353, encodeId=d53f1e9435351, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Dec 23 21:27:00 CST 2014, time=2014-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903054, encodeId=d3f9190305429, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon May 12 14:27:00 CST 2014, time=2014-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959015, encodeId=cb6a1959015e5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Feb 27 23:27:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868773, encodeId=38e71868e7317, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Mar 26 22:27:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294157, encodeId=277b129415e2b, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Feb 17 11:27:00 CST 2014, time=2014-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481818, encodeId=ce541481818ec, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Mon Feb 17 11:27:00 CST 2014, time=2014-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7432, encodeId=22b8e43296, content=小日本真强得很,尤其干细胞领域,确实处于依靠位置, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.132.226.159, createdTime=Sat Feb 15 23:37:00 CST 2014, time=2014-02-15, status=1, ipAttribution=)]
    2014-02-15 61.132.226.159

    小日本真强得很,尤其干细胞领域,确实处于依靠位置

    0

相关资讯

Liver int:一单位血小板对凝血状态影响甚微

肝硬化患者因存在脾功能亢进,血小板破坏增加,通常存在血小板计数减少,导致自发性出血风险增加。为了改善这一状况,临床上通常给予一单位(即一标准成人血小板量)的输注以预防出血,但究竟一标准成人血小板能起到多大的作用?是否能够有效改善患者的凝血状态?如何输注效果会更好?这些仍不清楚。意大利米兰安吉洛比安奇博诺米血友病和血栓形成研究中心Armando Tripodi等人对于上述问题进行了一系列研究,发现输

Nature:科学家在小鼠中发现新型骨髓干细胞

日前,来自英国爱丁堡大学和牛津大学的研究人员在小鼠中发现新型的骨髓干细胞,该干细胞能够产生大量的血小板。病人在化疗或骨髓移植后,往往会有血小板缺失现象,该新发现有助于研究人员开发新的恢复病人血小板水平的治疗方法。相关研究论文刊登在了近期出版的《自然》(Nature)杂志上。【原文下载】 血小板能够聚集在出血部位,促使血液迅速凝集,防止机体大量失血。 癌症治疗的一个常见副

J Psychiatr Res:初诊抑郁症与动脉粥样硬化相关

  近期发表于《精神病学研究杂志》(J Psychiatr Res)上的一项研究表明,相比健康对照组,初诊抑郁症患者体内的血小板CD62P(P-选择素)、动脉粥样硬化标志物(CD40,CD40L)、血清血小板因子4(PF4)和β-血小板球蛋白(β-TG)水平会有所升高,说明抑郁症与血栓和炎症状态相关,而这可能会加速动脉粥样硬化。   炎症在动脉粥样硬化疾病中扮演重要角色。目前

史旭波:正确认识血小板反应多样性

随着人们对血小板在动脉粥样硬化血栓形成事件中关键作用认识的不断深入,抗血小板治疗(阿司匹林和噻吩吡啶类药物如氯吡格雷)成为急性冠脉综合征(ACS)和接受经皮冠脉介入治疗(PCI)患者常规治疗的重要组成部分。但是,不同个体对于抗血小板药物治疗反应存在差异,这一现象被称为血小板反应多样性(VPR)。 鉴于不同个体对抗血小板治疗的反应存在多样性,抗血小板治疗后的血小板残余反应性也不同,对其进行

Blood:体外无限量制造人体红细胞和血小板新方法

临床上使用的红细胞和血小板一般是来自于献血,因此医院可能会在一段时间内出现“血荒”。 近日,波士顿大学医学院(Boston University School of Medicine)等机构的科学家们开发了一个新方法,成功使诱导多能干细胞(iPS)分化成为这两种细胞,能够在体外无限量制造人体红细胞和血小板。这一研究有望减少人们对献血的依赖,同时帮助科学家对多种疾病进行研究,例如镰状细胞病。相关研

2013年中华医学会抗血小板治疗中国专家共识

中华医学会心血管病学分会和中华心血管病杂志编辑委员会根据近年来抗血小板治疗药物相关临床试验结果,综合美国心脏病学学会基金会(ACCF)/美同心脏协会(AHA)、欧洲心脏病学学会(ESC)、心血管造影和介入治疗学会(SCAI)、欧洲卒中组织等权威机构发布的最新指南,中华医学会心血管病学分会、中华医学会神经科分会等国内学术机构发布的指南和我国心脑血管疾病防治的现状,组织相关专家撰写了本共识,以推进我国